Cross-Sector entity
Payoneer is the most frequent co-covered peer, appearing in 4 of the 7 tracked stories. Coverage clusters in earnings, which accounts for 3 of those 7, with the remainder spread across 2 other categories. 0% of these stories carry negative sentiment.
7 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Payoneer is the most frequent co-covered peer, appearing in 4 of the 7 tracked stories. Coverage clusters in earnings, which accounts for 3 of those 7, with the remainder spread across 2 other categories. 0% of these stories carry negative sentiment. GoodRx appears in 7 tracked Cross-Sector stories from February 26, 2026. The tracked stories average 9.4 original sources each.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GoodRx. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Payoneer reports Q4 results, missing estimates but providing 2026 guidance.
Bank Charter Application
Company files for a U.S. national bank charter with the OCC.
Stablecoin Integration
Payoneer adds stablecoin capabilities for cross-border business payments.
Payoneer Global Inc. reported Q4 2025 results that missed analyst expectations on both revenue and earnings, triggering a cautious market reaction. Despite the miss, the company signaled a major strategic shift by applying for a U.S. national bank charter and expanding into stablecoin-based cross-border settlements.
Payoneer missed top and bottom-line estimates for Q4 2025, triggering a stock decline despite a 12% core revenue growth forecast for 2026. The company is aggressively shifting focus toward larger SMBs, stablecoin integration, and a U.S. national bank charter to solidify its cross-border payment dominance.
Payoneer reported robust Q4 2025 results, driven by double-digit growth in B2B volume and strategic expansion into emerging markets. The broader mid-cap landscape shows a divergence between high-growth consumer brands like Celsius and R&D-heavy biotech firms navigating a complex regulatory environment.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Schrödinger and GoodRx reported full-year 2025 results, demonstrating the growing financial impact of AI-driven computational platforms in drug discovery and healthcare. These reports, alongside Churchill Downs' record performance, highlight a broader trend of data-centric companies leveraging machine learning to optimize specialized market verticals.
GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.
